Eli Lilly and Company (NYSE:LLY) Shares Up 1.4% – Time to Buy?

Eli Lilly and Company (NYSE:LLY) shares rose 1.4% during mid-day trading on Thursday . The company traded as high as $1,232.00 and last traded at $1,208.3670. 3,247,617 shares changed hands during trading, an increase of 0% from the average daily volume of 3,238,143 shares. The stock had previously closed at $1,191.74.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and market commentary remain constructive on Lilly’s long-term outlook, citing leadership in GLP-1 therapies, an expanding pipeline, and a diversified growth strategy. Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?
• Positive Sentiment: GLP-1 demand is still viewed as a major industry growth driver, which supports Lilly’s obesity and diabetes franchise. Can pharma sustain its $2T trajectory?
• Positive Sentiment: TipRanks said AI could become a meaningful long-term growth tailwind for Eli Lilly by improving drug discovery and development productivity. AI Is the Ultimate Growth Tailwind for Eli Lilly (LLY). Here’s Why
• Positive Sentiment: Several analysts reiterated bullish views heading into earnings, pointing to multiple catalysts that could drive further upside. Several Analysts Pounds the Table on Eli Lilly Stock (LLY) Heading into Earnings
• Neutral Sentiment: Lilly also announced regional management changes in Korea and Romania, which appear operational rather than market-moving. Eli Lilly Korea names Komasu Seiya new representative
• Neutral Sentiment: Some coverage noted Lilly is still priced at a premium, and one analyst trimmed FY2027 EPS estimates slightly, suggesting valuation remains a watch item. Promising Pharmaceutical Stocks To Keep An Eye On – July 1st
• Negative Sentiment: Investors are also watching risks in China, including a U.S. lawmakers’ probe into Lilly’s clinical trial activities and a separate generic patent challenge to tirzepatide. Eli Lilly (LLY) Faces China Trial Security Probe From U.S. Lawmakers
• Negative Sentiment: China-related patent litigation over tirzepatide could create longer-term competitive and legal pressure on Lilly’s obesity franchise. China’s Hybio Challenges Eli Lilly Patents With First Generic Filing for Blockbuster Weight-Loss Drug Tirzepatide

Analyst Ratings Changes

Several brokerages recently issued reports on LLY. The Goldman Sachs Group restated a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Berenberg Bank increased their target price on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a report on Monday, June 22nd. Guggenheim reissued a “buy” rating and set a $1,183.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, May 5th. UBS Group reissued a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Finally, Leerink Partners increased their price objective on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research note on Thursday, June 25th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $1,235.07.

Eli Lilly and Company Trading Up 1.4%

The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The stock has a market capitalization of $1.14 trillion, a price-to-earnings ratio of 42.93, a price-to-earnings-growth ratio of 1.49 and a beta of 0.51. The business has a 50 day simple moving average of $1,053.61 and a 200-day simple moving average of $1,025.60.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the prior year, the company posted $3.34 EPS. The company’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts predict that Eli Lilly and Company will post 35.74 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

Institutional Trading of Eli Lilly and Company

A number of institutional investors and hedge funds have recently made changes to their positions in LLY. Brighton Jones LLC boosted its position in shares of Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares during the period. Revolve Wealth Partners LLC boosted its holdings in Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after acquiring an additional 40 shares during the period. Schnieders Capital Management LLC. grew its position in Eli Lilly and Company by 16.7% in the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after acquiring an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC purchased a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $356,000. Finally, Nebula Research & Development LLC purchased a new stake in Eli Lilly and Company during the 2nd quarter worth $749,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.